Ravina Barrett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ravina Barrett has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Brian Birch
University Hospital Southampton NHS Foundation Trust Southampton UK
2 shared publications David Culliford
Faculty of Medicine, University of Southampton, Southampton, UK
2 shared publicationsSharon X Lin
Faculty of Health Sciences, University of Southampton, Southampton, UK
2 shared publications- Simon D. S. Fraser
School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK
2 shared publications Adam Rischin
Alfred Health
1 shared publication- Alsaeed Bashayr Ali
School of Applied Sciences, Cockcroft Building, University of Brighton , Moulsecoomb, Brighton BN2 4GJ , UK
1 shared publication
Latest Publications
- Open Access
- 12 December 2024
- Published byĀ ElsevierĀ inĀ Future Healthcare Journal
- Vol.Ā 11 Ā (4) , 100214
Exploring innovations, challenges and visions for tomorrowās healthcare
- 12 December 2024
- Published byĀ ElsevierĀ inĀ Future Healthcare Journal
- Vol.Ā 11 Ā (4) , 100214
Open AccessExploring innovations, challenges and visions for tomorrowās healthcare
- Open Access
- 10 October 2023
- Published byĀ WileyĀ inĀ BJUI Compass
- Vol.Ā 5 Ā (1) , 17-28
Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic metaāanalysis
Objective: This systematic metaāanalysis aimed to assess the effectiveness of triptorelin therapy in reducing lower urinary tract symptoms (LUTS) in men with prostate cancer (PCa).Methods: The Preferred Reporting Items for Systematic Reviews and MetaāAnalyses (PRISMA) guidelines were followed. PubMed, Web of Science and EMBASE databases were searched for studies conducted between 2013 and 2023. Eligible studies included PCa patients undergoing androgen deprivation therapy (ADT) with triptorelin, with reported baseline and followāup International Prostate Symptom Scores (IPSS) and quality of life (QoL) data. The NewcastleāOttawa Scale (NOS) was used to assess the risk of bias, and a randomāeffects model was applied for the metaāanalysis.Results: A total of 29 articles were identified, and three studies met the inclusion criteria. Triptorelin therapy showed a clinically significant reduction in IPSS over 48 weeks in PCa patients with moderate to severe LUTS. The metaāanalysis revealed a pooled effect size of 1.05 (95% CI: 0.65; 1.45), indicating a statistically significant improvement in LUTS. QoL also improved in patients receiving triptorelin therapy, although heterogeneity among the studies and a moderate to high risk of bias were noted.Conclusion: Triptorelin therapy demonstrated a positive impact on LUTS in PCa patients. The metaāanalysis showed significant reductions in IPSS scores and improved QoL after 48 weeks of triptorelin treatment. However, the results should be interpreted cautiously due to study heterogeneity and potential biases. Further wellādesigned studies are needed to confirm these findings and determine the optimal use of triptorelin for managing LUTS in men with PCa.Implications for Practice: Triptorelin therapy may offer an effective treatment option for men with PCa experiencing moderate to severe LUTS. Its positive impact on QoL can lead to improved patient wellābeing and treatment adherence. Clinicians should consider triptorelin as a potential treatment choice, especially in patients who may be reluctant to undergo surgical interventions for their LUTS. However, careful patient selection and close monitoring are essential due to the observed study heterogeneity and risk of bias. Future research should focus on evaluating triptorelin's costāeffectiveness and comparing its efficacy with other LHāRH agonists in managing LUTS in PCa patients.Video URL (Reviewers/Editors to select from) Link 1: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=071419c8-1ad5-4502-a222-b04300c2ca5eLink 2: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=b6305a8a-b977-4fcd-a69e-b04300bed728
- 10 October 2023
- Published byĀ WileyĀ inĀ BJUI Compass
- Vol.Ā 5 Ā (1) , 17-28
Open AccessTriptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic metaāanalysis
Objective: This systematic metaāanalysis aimed to assess the effectiveness of triptorelin therapy in reducing lower urinary tract symptoms (LUTS) in men with prostate cancer (PCa).Methods: The Preferred Reporting Items for Systematic Reviews and MetaāAnalyses (PRISMA) guidelines were followed. PubMed, Web of Science and EMBASE databases were searched for studies conducted between 2013 and 2023. Eligible studies included PCa patients undergoing androgen deprivation therapy (ADT) with triptorelin, with reported baseline and followāup International Prostate Symptom Scores (IPSS) and quality of life (QoL) data. The NewcastleāOttawa Scale (NOS) was used to assess the risk of bias, and a randomāeffects model was applied for the metaāanalysis.Results: A total of 29 articles were identified, and three studies met the inclusion criteria. Triptorelin therapy showed a clinically significant reduction in IPSS over 48 weeks in PCa patients with moderate to severe LUTS. The metaāanalysis revealed a pooled effect size of 1.05 (95% CI: 0.65; 1.45), indicating a statistically significant improvement in LUTS. QoL also improved in patients receiving triptorelin therapy, although heterogeneity among the studies and a moderate to high risk of bias were noted.Conclusion: Triptorelin therapy demonstrated a positive impact on LUTS in PCa patients. The metaāanalysis showed significant reductions in IPSS scores and improved QoL after 48 weeks of triptorelin treatment. However, the results should be interpreted cautiously due to study heterogeneity and potential biases. Further wellādesigned studies are needed to confirm these findings and determine the optimal use of triptorelin for managing LUTS in men with PCa.Implications for Practice: Triptorelin therapy may offer an effective treatment option for men with PCa experiencing moderate to severe LUTS. Its positive impact on QoL can lead to improved patient wellābeing and treatment adherence. Clinicians should consider triptorelin as a potential treatment choice, especially in patients who may be reluctant to undergo surgical interventions for their LUTS. However, careful patient selection and close monitoring are essential due to the observed study heterogeneity and risk of bias. Future research should focus on evaluating triptorelin's costāeffectiveness and comparing its efficacy with other LHāRH agonists in managing LUTS in PCa patients.Video URL (Reviewers/Editors to select from) Link 1: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=071419c8-1ad5-4502-a222-b04300c2ca5eLink 2: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=b6305a8a-b977-4fcd-a69e-b04300bed728
- 7 February 2023
- Published byĀ Oxford University Press (OUP)Ā inĀ International Journal of Pharmacy Practice
- Vol.Ā 31 Ā (2) , 176-182
Community pharmacistsā knowledge of substandard and falsified medicines in clinical practice: a cross-sectional survey in Saudi Arabia
The main objective of this study was to explore community pharmacistsā knowledge of substandard and falsified medicines (SFs). A descriptive cross-sectional study was conducted with community pharmacists in the Kingdom of Saudi Arabia using a pre-validated electronic survey. Ninety-two community pharmacists participated in this study. Many of the respondents (68.5%) had no experience with identifying SFs. We identified a concerning trend of under-reporting SFs (P < 0.003). Respondents reported that SFs constitutes 1ā5% of medicines, with weight loss medicines being the most targeted for falsification. Most of the respondents had a low level of awareness about the newly implemented anti-counterfeit system in Saudi Arabia called the āDrug Track and Trace Systemā (28.3% not really, 23.1% not at all). Respondents showed low levels of knowledge about technologies available to detect SFs (P < 0.01). Community pharmacistsā self-reported awareness and knowledge of SFs in Saudi Arabia was inadequate; this deficiency may affect their ability to protect their patients from potential harm by combating SFs. As a regulatory body responsible for issues related to SFs, the Saudi Food and Drug Authority should develop an action plan to equip community pharmacists with training in SFs to enhance their ability to respond to SFs.
- 7 February 2023
- Published byĀ Oxford University Press (OUP)Ā inĀ International Journal of Pharmacy Practice
- Vol.Ā 31 Ā (2) , 176-182
Community pharmacistsā knowledge of substandard and falsified medicines in clinical practice: a cross-sectional survey in Saudi Arabia
The main objective of this study was to explore community pharmacistsā knowledge of substandard and falsified medicines (SFs). A descriptive cross-sectional study was conducted with community pharmacists in the Kingdom of Saudi Arabia using a pre-validated electronic survey. Ninety-two community pharmacists participated in this study. Many of the respondents (68.5%) had no experience with identifying SFs. We identified a concerning trend of under-reporting SFs (P < 0.003). Respondents reported that SFs constitutes 1ā5% of medicines, with weight loss medicines being the most targeted for falsification. Most of the respondents had a low level of awareness about the newly implemented anti-counterfeit system in Saudi Arabia called the āDrug Track and Trace Systemā (28.3% not really, 23.1% not at all). Respondents showed low levels of knowledge about technologies available to detect SFs (P < 0.01). Community pharmacistsā self-reported awareness and knowledge of SFs in Saudi Arabia was inadequate; this deficiency may affect their ability to protect their patients from potential harm by combating SFs. As a regulatory body responsible for issues related to SFs, the Saudi Food and Drug Authority should develop an action plan to equip community pharmacists with training in SFs to enhance their ability to respond to SFs.
- Open Access
Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset
Objective To investigate monthly prescription refills for common immunosuppressive/immunomodulatory therapy (sulfasalazine, hydroxychloroquine, azathioprine, methotrexate, leflunomide) prescriptions in England during the complete first wave of the COVID-19 pandemic. Secondary analysis examined unit cost analysis and regional use. Design and setting A national cohort of community-based, primary care patients who anonymously contribute data to the English Prescribing Dataset, dispensed in the community in England, were included. Descriptive statistics and interrupted time series analysis over 25 months (14 months before, 11 months after first lockdown) were evaluated (January 2019 to January 2021, with March 2020 as the cut-off point). Outcome measures Prescription reimbursement variance in period before the pandemic as compared with after the first lockdown. Results Fluctuation in monthly medicines use is noted in March 2020: a jump is observed for hydroxychloroquine (Mann-Whitney, SE 14.652, standardised test statistic 1.911, p value=0.059) over the study period. After the first lockdown, medicines use fluctuated, with wide confidence intervals. Unit-cost prices changed substantially: sulfasalazine 33% increase, hydroxychloroquine 98% increase, azathioprine 41% increase, methotrexate 41% increase, leflunomide 20% decrease. London showed the least quantity variance, suggesting more homogeneous prescribing and patient access compared with Midlands and East of England, suggesting that some patients may have received medication over/under requirement, representing potential resource misallocation and a proxy for adherence rates. Changepoint detection revealed four out of the five medicinesā use patterns changed with a strong signal only for sulfasalazine in March/April 2020. Conclusions Findings potentially present lower rates of adherence because of the pandemic, suggesting barriers to care access. Unit price increases are likely to have severe budget impacts in the UK and potentially globally. Timely prescription refills for patients taking immunosuppressive/immunomodulatory therapies are recommended. Healthcare professionals should identify patients on these medicines and assess their prescription-day coverage, with planned actions to flag and follow-up adherence concerns in patients.
Open AccessImpact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset
Objective To investigate monthly prescription refills for common immunosuppressive/immunomodulatory therapy (sulfasalazine, hydroxychloroquine, azathioprine, methotrexate, leflunomide) prescriptions in England during the complete first wave of the COVID-19 pandemic. Secondary analysis examined unit cost analysis and regional use. Design and setting A national cohort of community-based, primary care patients who anonymously contribute data to the English Prescribing Dataset, dispensed in the community in England, were included. Descriptive statistics and interrupted time series analysis over 25 months (14 months before, 11 months after first lockdown) were evaluated (January 2019 to January 2021, with March 2020 as the cut-off point). Outcome measures Prescription reimbursement variance in period before the pandemic as compared with after the first lockdown. Results Fluctuation in monthly medicines use is noted in March 2020: a jump is observed for hydroxychloroquine (Mann-Whitney, SE 14.652, standardised test statistic 1.911, p value=0.059) over the study period. After the first lockdown, medicines use fluctuated, with wide confidence intervals. Unit-cost prices changed substantially: sulfasalazine 33% increase, hydroxychloroquine 98% increase, azathioprine 41% increase, methotrexate 41% increase, leflunomide 20% decrease. London showed the least quantity variance, suggesting more homogeneous prescribing and patient access compared with Midlands and East of England, suggesting that some patients may have received medication over/under requirement, representing potential resource misallocation and a proxy for adherence rates. Changepoint detection revealed four out of the five medicinesā use patterns changed with a strong signal only for sulfasalazine in March/April 2020. Conclusions Findings potentially present lower rates of adherence because of the pandemic, suggesting barriers to care access. Unit price increases are likely to have severe budget impacts in the UK and potentially globally. Timely prescription refills for patients taking immunosuppressive/immunomodulatory therapies are recommended. Healthcare professionals should identify patients on these medicines and assess their prescription-day coverage, with planned actions to flag and follow-up adherence concerns in patients.
- Open Access
- 29 November 2022
- Published byĀ Taylor & FrancisĀ inĀ Expert Opinion on Drug Safety
- Vol.Ā 22 Ā (12) , 1289-1299
A cross-sectional study on substandard and falsified medicines (fake or counterfeit drugs) in UK pharmacies during the COVID-19 pandemic
Failure of the Falsified Medicines Directive (FMD) in the UK could mean that substandard and falsified medicines (SFs) enter the legitimate supply chain. Does this risk UK patientsā health? Readine...
- 29 November 2022
- Published byĀ Taylor & FrancisĀ inĀ Expert Opinion on Drug Safety
- Vol.Ā 22 Ā (12) , 1289-1299
Open AccessA cross-sectional study on substandard and falsified medicines (fake or counterfeit drugs) in UK pharmacies during the COVID-19 pandemic
Failure of the Falsified Medicines Directive (FMD) in the UK could mean that substandard and falsified medicines (SFs) enter the legitimate supply chain. Does this risk UK patientsā health? Readine...
- Open Access
- 24 November 2022
- Published byĀ SAGE PublicationsĀ inĀ Therapeutic Advances in Cardiovascular Disease
- Vol.Ā 16
Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of Englandās prescription data during the COVID-19 pandemic (January 2019 to October 2020)
Background: Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours. Aim: This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic. Methods: A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemicās onset. Statistical variation was the outcome of interest. Results: Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (MarchāOctober 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications. Conclusion: A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi
- 24 November 2022
- Published byĀ SAGE PublicationsĀ inĀ Therapeutic Advances in Cardiovascular Disease
- Vol.Ā 16
Open AccessImpact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of Englandās prescription data during the COVID-19 pandemic (January 2019 to October 2020)
Background: Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours. Aim: This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic. Methods: A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemicās onset. Statistical variation was the outcome of interest. Results: Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (MarchāOctober 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications. Conclusion: A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi
- Open Access
- 30 May 2022
- Published byĀ Taylor & FrancisĀ inĀ Current Medical Research and Opinion
- Vol.Ā 38 Ā (7) , 1081-1092
Impact of the COVID-19 pandemic on Englandās national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019āFebruary 2021)
Background: Direct-acting oral anticoagulants (DOACs) were developed as an alternative to warfarin to treat and prevent thromboembolism, including stroke prevention in non-valvular atrial fibrillation patients. The COVID-19 pandemic could increase the risk of stroke and/or the risk of bleeding in patients due to nonadherence or sub/supra-optimal dosing. Objective: To investigate DOAC prescription trends in Englandās community settings during the complete first wave of COVID-19 pandemic. Methods: Descriptive and interrupted time series (ITS) analyses were conducted to examine the prescription patterns of DOACs (dabigatran, rivaroxaban, apixaban and edoxaban) and warfarin for primary care patients in the English Prescribing Dataset from January 2019 to February 2021, with March 2020 as the cut-off point. Results: A 19% increase in mean DOACās accompanied with 20% warfarin prescriptions decline was observed. ITS modelling showed an increase in DOAC prescription volume in March 2020 (+7 million items, p = 0.008). The pre-existing upward trend in DOAC prescriptions slowed during the period (-427,000 items, p = 0.007). Apixaban was the most frequently used DOAC and had the largest step-change in March 2020 (+5 million items, p = 0.010). The mean monthly combined cost of DOACs and warfarin was higher during the period. DOAC prescription trends were consistent across Englandās regions. Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.
- 30 May 2022
- Published byĀ Taylor & FrancisĀ inĀ Current Medical Research and Opinion
- Vol.Ā 38 Ā (7) , 1081-1092
Open AccessImpact of the COVID-19 pandemic on Englandās national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019āFebruary 2021)
Background: Direct-acting oral anticoagulants (DOACs) were developed as an alternative to warfarin to treat and prevent thromboembolism, including stroke prevention in non-valvular atrial fibrillation patients. The COVID-19 pandemic could increase the risk of stroke and/or the risk of bleeding in patients due to nonadherence or sub/supra-optimal dosing. Objective: To investigate DOAC prescription trends in Englandās community settings during the complete first wave of COVID-19 pandemic. Methods: Descriptive and interrupted time series (ITS) analyses were conducted to examine the prescription patterns of DOACs (dabigatran, rivaroxaban, apixaban and edoxaban) and warfarin for primary care patients in the English Prescribing Dataset from January 2019 to February 2021, with March 2020 as the cut-off point. Results: A 19% increase in mean DOACās accompanied with 20% warfarin prescriptions decline was observed. ITS modelling showed an increase in DOAC prescription volume in March 2020 (+7 million items, p = 0.008). The pre-existing upward trend in DOAC prescriptions slowed during the period (-427,000 items, p = 0.007). Apixaban was the most frequently used DOAC and had the largest step-change in March 2020 (+5 million items, p = 0.010). The mean monthly combined cost of DOACs and warfarin was higher during the period. DOAC prescription trends were consistent across Englandās regions. Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.
- Open Access
- 21 April 2022
- Published byĀ University of Huddersfield PressĀ inĀ British Journal of Pharmacy
- Vol.Ā 7 Ā (1)
An evaluation of community pharmacists' perception of e-cigarette: An English cross-sectional survey with geospatial analysis.
We wanted to establish prevalence of e-cigarette sale via Englishcommunity pharmacies. A cross-sectional survey of 500 retail-pharmacies was completed.Seventeen out of the 66respondents sold e-cigarettes, indicating a sales-prevalence of 25.76%. NRTwas widely available for sale (n=16, 94.1%), cessation services were lessfrequently available (n=7, 41.2%), or not available (n=9, 52.9%). āDailysmokersā were likely to use e-cigarette (n=8, 47.1%). Accessories were sold to0-2 people (n=13, 76.5%), ϲ p=2.454 x 10-4. Young women purchasede-cigarettes (n=4, 23.5%), p=0.049, which were placed on top of the counter (n=7,41.2%), reflecting āimpulse salesā strategy. NRT was available forself-selection (n=14, 82.4%) (p=0.004), however staff-assistance was required(n=12, 70.6%), posing barriers. Costs for e-cigarette (Ā£10.99-Ā£29.99) versusNRT (Ā£4.25-Ā£35.99) represents value for money. Labelling and packaging werefound to be attractive, p=0.049, fashionable, colourful p=0.049, healthy,potentially breaching laws. All respondents provided NRT counselling, p<1x10-8.Less than half (n=8, 47.1%) provide e-cigaretteās counselling, while a majority(n=9, 52.9%) did not. Eight respondents describe 22 flavours, providing goodmouth feel. Aggregate ādeprivedā versus āaffluentā analysis revels interestinginsights. We find some support of non-smokers initiating use. Pharmacists help patientsbut have limited support. We make recommendations to improve practice.
- 21 April 2022
- Published byĀ University of Huddersfield PressĀ inĀ British Journal of Pharmacy
- Vol.Ā 7 Ā (1)
Open AccessAn evaluation of community pharmacists' perception of e-cigarette: An English cross-sectional survey with geospatial analysis.
We wanted to establish prevalence of e-cigarette sale via Englishcommunity pharmacies. A cross-sectional survey of 500 retail-pharmacies was completed.Seventeen out of the 66respondents sold e-cigarettes, indicating a sales-prevalence of 25.76%. NRTwas widely available for sale (n=16, 94.1%), cessation services were lessfrequently available (n=7, 41.2%), or not available (n=9, 52.9%). āDailysmokersā were likely to use e-cigarette (n=8, 47.1%). Accessories were sold to0-2 people (n=13, 76.5%), ϲ p=2.454 x 10-4. Young women purchasede-cigarettes (n=4, 23.5%), p=0.049, which were placed on top of the counter (n=7,41.2%), reflecting āimpulse salesā strategy. NRT was available forself-selection (n=14, 82.4%) (p=0.004), however staff-assistance was required(n=12, 70.6%), posing barriers. Costs for e-cigarette (Ā£10.99-Ā£29.99) versusNRT (Ā£4.25-Ā£35.99) represents value for money. Labelling and packaging werefound to be attractive, p=0.049, fashionable, colourful p=0.049, healthy,potentially breaching laws. All respondents provided NRT counselling, p<1x10-8.Less than half (n=8, 47.1%) provide e-cigaretteās counselling, while a majority(n=9, 52.9%) did not. Eight respondents describe 22 flavours, providing goodmouth feel. Aggregate ādeprivedā versus āaffluentā analysis revels interestinginsights. We find some support of non-smokers initiating use. Pharmacists help patientsbut have limited support. We make recommendations to improve practice.
- 24 January 2022
- Published byĀ Springer NatureĀ inĀ DARU Journal of Pharmaceutical Sciences
- Vol.Ā 30 Ā (1) , 59-66
Calcineurin inhibitors and related medicines: a cohort study examining Englandās primary care prescription changes during the COVID-19 pandemic (January 2019 to March 2021)
Purpose To examine the impact of the COVID-19 pandemic on calcineurin inhibitors and related prescriptions for community patients in England. Methods Data from all primary-care patients who had calcineurin inhibitors prescriptions, dispensed in the community in England were included. Descriptive statistics and interrupted time series analysis over 27 months (15 months before and 12 months after 1st lockdown) was evaluated. Results Descriptive statistics show that mean values have declined since the pandemicās onset. Over the 27 months: mean Tacrolimus 865,045 doses, standard deviation (SD) 76,147 doses, with 95% CI 834,923, 895,168, (min 567,508, max 1,010,900), ciclosporin 315,496 doses, SD 40,094, 95% CI 299,635, 331,356 (min 191,281, max 382,253) and sirolimus 21,384 doses, SD 2,610, 95% CI 20,352, 22,417 (min 13,022, max 26,156). Analysis of variance between the pre- and post- periods show significant variations in quantities of tacrolimus F 7.432, p = 0.012, ciclosporin F 33.147, p < 0.001 and sirolimus F 18.596, p < 0.001 (1df), mirrored in price analysis. The Interrupted Time Series (ARIMA Modelling) shows declining trends. After the pandemic's onset, a statistically significant downward trend in quantity for tacrolimus p = 0.008 is observed, with an estimated monthly decline of 14,524 doses, ciclosporin p = 0.185, with an estimated decline of 2,161 doses and sirolimus p = 0.002 with an estimated decline of 485 doses, along with declining prices. Conclusion A decrease in prescription medicines use raises concerns for the care of (renal) transplant patients. Patients are encouraged to discuss their planned care with their doctor, secure supplies and remain adherent to their medication. Graphical abstract
- 24 January 2022
- Published byĀ Springer NatureĀ inĀ DARU Journal of Pharmaceutical Sciences
- Vol.Ā 30 Ā (1) , 59-66
Calcineurin inhibitors and related medicines: a cohort study examining Englandās primary care prescription changes during the COVID-19 pandemic (January 2019 to March 2021)
Purpose To examine the impact of the COVID-19 pandemic on calcineurin inhibitors and related prescriptions for community patients in England. Methods Data from all primary-care patients who had calcineurin inhibitors prescriptions, dispensed in the community in England were included. Descriptive statistics and interrupted time series analysis over 27 months (15 months before and 12 months after 1st lockdown) was evaluated. Results Descriptive statistics show that mean values have declined since the pandemicās onset. Over the 27 months: mean Tacrolimus 865,045 doses, standard deviation (SD) 76,147 doses, with 95% CI 834,923, 895,168, (min 567,508, max 1,010,900), ciclosporin 315,496 doses, SD 40,094, 95% CI 299,635, 331,356 (min 191,281, max 382,253) and sirolimus 21,384 doses, SD 2,610, 95% CI 20,352, 22,417 (min 13,022, max 26,156). Analysis of variance between the pre- and post- periods show significant variations in quantities of tacrolimus F 7.432, p = 0.012, ciclosporin F 33.147, p < 0.001 and sirolimus F 18.596, p < 0.001 (1df), mirrored in price analysis. The Interrupted Time Series (ARIMA Modelling) shows declining trends. After the pandemic's onset, a statistically significant downward trend in quantity for tacrolimus p = 0.008 is observed, with an estimated monthly decline of 14,524 doses, ciclosporin p = 0.185, with an estimated decline of 2,161 doses and sirolimus p = 0.002 with an estimated decline of 485 doses, along with declining prices. Conclusion A decrease in prescription medicines use raises concerns for the care of (renal) transplant patients. Patients are encouraged to discuss their planned care with their doctor, secure supplies and remain adherent to their medication. Graphical abstract
- Open Access
- 3 November 2021
- Published byĀ Royal College of General PractitionersĀ inĀ BJGP Open
- Vol.Ā 6 Ā (1)
Characterising risk of non-steroidal anti-inflammatory drug-related acute kidney injury: a retrospective cohort study
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for pain and inflammation. NSAID complications include acute kidney injury (AKI), causing burden to patients and health services through increased morbidity, mortality, and hospital admissions.Aim: To measure the extent of NSAID prescribing in an adult population, the degree to which patients with potential higher risk of AKI were exposed to NSAIDs, and to quantify their risk of AKI.Design & setting: Retrospective 2-year closed-cohort study.Method: A retrospective cohort of adults was identified from a pseudonymised electronic primary care database in Hampshire, UK. The cohort had clinical information, prescribing data, and complete GP- and hospital-ordered biochemistry data. NSAID exposure (minimum one prescription in a 2-month period) was categorised as never, intermittent, and continuous, and first AKI using the national AKI e-alert algorithm. Descriptive statistics and logistic regression were used to explore NSAID prescribing patterns and AKI risk.Results: The baseline population was 702 265. NSAID prescription fell from 19 364 (2.8%) to 16 251 (2.4%) over 2 years. NSAID prescribing was positively associated with older age, female sex, greater socioeconomic deprivation, and certain comorbidities (diabetes, hypertension, osteoarthritis, and rheumatoid arthritis) and negatively with cardiovascular disease (CVD) and heart failure. Among those prescribed NSAIDs, AKI was associated with older age, greater deprivation, chronic kidney disease (CKD), CVD, heart failure, diabetes, and hypertension.Conclusion: Despite generally good prescribing practice, NSAID prescribing was identified in some people at higher risk of AKI (for example, patients with CKD and older) for whom medication review and NSAID deprescribing should be considered.
- 3 November 2021
- Published byĀ Royal College of General PractitionersĀ inĀ BJGP Open
- Vol.Ā 6 Ā (1)
Open AccessCharacterising risk of non-steroidal anti-inflammatory drug-related acute kidney injury: a retrospective cohort study
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for pain and inflammation. NSAID complications include acute kidney injury (AKI), causing burden to patients and health services through increased morbidity, mortality, and hospital admissions.Aim: To measure the extent of NSAID prescribing in an adult population, the degree to which patients with potential higher risk of AKI were exposed to NSAIDs, and to quantify their risk of AKI.Design & setting: Retrospective 2-year closed-cohort study.Method: A retrospective cohort of adults was identified from a pseudonymised electronic primary care database in Hampshire, UK. The cohort had clinical information, prescribing data, and complete GP- and hospital-ordered biochemistry data. NSAID exposure (minimum one prescription in a 2-month period) was categorised as never, intermittent, and continuous, and first AKI using the national AKI e-alert algorithm. Descriptive statistics and logistic regression were used to explore NSAID prescribing patterns and AKI risk.Results: The baseline population was 702 265. NSAID prescription fell from 19 364 (2.8%) to 16 251 (2.4%) over 2 years. NSAID prescribing was positively associated with older age, female sex, greater socioeconomic deprivation, and certain comorbidities (diabetes, hypertension, osteoarthritis, and rheumatoid arthritis) and negatively with cardiovascular disease (CVD) and heart failure. Among those prescribed NSAIDs, AKI was associated with older age, greater deprivation, chronic kidney disease (CKD), CVD, heart failure, diabetes, and hypertension.Conclusion: Despite generally good prescribing practice, NSAID prescribing was identified in some people at higher risk of AKI (for example, patients with CKD and older) for whom medication review and NSAID deprescribing should be considered.